Sevoflurane-induced preconditioning: Impact of protocol and aprotinin administration on infarct size and endothelial nitric-oxide synthase phosphorylation in the rat heart in vivo

Anesthesiology

Volumn 113, Issue 6, 2010, Pages 1289-1298

  Frädorf, Jan ^a   Huhn, Ragnar ^c   Weber, Nina C ^b   Ebel, Dirk ^d   Wingert, Nadja ^e   Preckel, Benedikt ^a   Toma, Octavian ^a   Schlack, Wolfgang ^a   Hollmann, Markus W ^b  

^a Department of Anesthesiology ^*  (Canada)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d SLINGELAND HOSPITAL   (Netherlands)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; ENDOTHELIAL NITRIC OXIDE SYNTHASE; SEVOFLURANE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME PHOSPHORYLATION; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; IN VIVO STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REPERFUSION INJURY;

EID: 78650180072     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3181f97fec     Document Type: Article

References (44)

1. Frässdorf J, De HertS, Schlack W: Anaesthesia and myocar-dial ischaemia/reperfusion injury. Br J Anaesth 2009; 103: 89-98
2. De Hert SG, ten Broecke PW, Mertens E, Van Sommeren EW, De Blier IG, Stockman BA, Rodrigus IE: Sevoflurane but not propofol preserves myocardial function in coronary surgery patients. ANESTHESIOLOGY 2002; 97:42-9
3. Weber NC, Schlack W: Inhalational anaesthetics and car-dioprotection. Handb Exp Pharmacol 2008; 182:187-207
4. De Hert SG, Preckel B, Schlack WS: Update on inhalational anaesthetics. Curr Opin Anaesthesiol 2009; 22:491-5
5. De Hert SG, Preckel B, Hollmann MW, Schlack WS: Drugs mediating myocardial protection. Eur J Anaesthesiol 2009; 26:985-95
6. Frässdorf J, Borowski A, Ebel D, Feindt P, Hermes M, Meemann T, Weber R, Müllenheim J, Weber NC, Preckel B, Schlack W: Impact of preconditioning protocol on anesthetic-induced cardioprotection in patients having coronary artery bypass surgery. J Thorac Cardiovasc Surg 2009; 137:1436-42
7. Riess ML, Kevin LG, Camara AK, Heisner JS, Stowe DF: Dual exposure to sevoflurane improves anesthetic preconditioning in intact hearts. ANESTHESIOLOGY 2004; 100:569-74
8. Lange M, Redel A, Smul TM, Lotz C, Nefzger T, Stumpner J, Blomeyer C, Gao F, Roewer N, Kehl F: Desflurane-induced preconditioning has a threshold that is lowered by repetitive application and is mediated by beta 2-adrenergic receptors. J Cardiothorac Vasc Anesth 2009; 23:607-13
9. Sandhu R, Diaz RJ, Mao GD, Wilson GJ: Ischemic preconditioning: Differences in protection and susceptibility to blockade with single-cycle versus multicycle transient ischemia. Circulation 1997; 96:984-95
10. Mangano DT, Tudor IC, Dietzel C, Multicenter Study of Periop-erative Ischemia Research Group, Ischemia Research and Education Foundation: The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354:353-65
11. Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, Teoh K, Duke PC, Arellano R, Blajchman MA, Bussières JS, Côté D, Karski J, Martineau R, Robblee JA, Rodger M, Wells G, Clinch J, Pretorius R, BART Inves-tigators: A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358:2319-31
12. Myles PS: Aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 359:1181-2
13. Porte RJ, Mallette SV, Burroughs AK: Aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 359:1181-2
14. Hendrikx M, Rega F, Jamaer L, Valkenborgh T, Gutermann H, Mees U: Na(+)/H(+)-exchange inhibition and aprotinin administration: Promising tools for myocardial protection during minimally invasive CABG. Eur J Cardiothorac Surg 2001; 19:633-9
15. Pruefer D, Buerke U, Khalil M, Dahm M, Darius H, Oelert H, Buerke M: Cardioprotective effects of the serine protease inhibitor aprotinin after regional ischemia and reper-fusion on the beating heart. J Thorac Cardiovasc Surg 2002; 124:942-9
16. Bukhari EA, Krukenkamp IB, Burns PG, Gaudette GR, Schulman JJ, al-Fagih MR, Levitsky S: Does aprotinin increase the myocardial damage in the setting of ischemia and preconditioning? Ann Thorac Surg 1995; 60:307-10
17. Chao J, Yin H, Gao L, Hagiwara M, Shen B, Yang ZR, Chao L: Tissue kallikrein elicits cardioprotection by direct kinin b2 receptor activation independent of kinin formation. Hypertension 2008; 52:715-20
18. Inamura Y, Miyamae M, Sugioka S, Kaneda K, Okusa C, Onishi A, Domae N, Kotani J, Figueredo VM: Aprotinin abolishes sevoflurane postconditioning by inhibiting nitric oxide production and phosphorylation of protein kinase C-S and glycogen synthase kinase 3/3. ANESTHESIOLOGY 2009; 111:1036-43
19. Ulker S, McKeown PP, Bayraktutan U: Aprotinin impairs coronary endothelial function and down-regulates endothelial NOS in rat coronary microvascular endothelial cells. Cardiovasc Res 2002; 55:830-7
20. Smul TM, Lange M, Redel A, Stumpner J, Lotz CA, Roewer N, Kehl F: Desflurane-induced cardioprotection against ischemia-reperfusion injury depends on timing. J Cardiothorac Vasc Anesth 2009; 23:600-6
21. Amour J, Brzezinska AK, Weihrauch D, Billstrom AR, Zielonka J, Krolikowski JG, Bienengraeber MW, Warltier DC, Pratt PF Jr, Kersten JR: Role of heat shock protein 90 and endothelial nitric oxide synthase during early anesthetic and ischemic preconditioning. ANESTHESIOLOGY 2009; 110:317-25
22. Obal D, Preckel B, Scharbatke H, Mullenheim J, Hoterkes F, Thamer V, Schlack W: One MAC of sevoflurane provides protection against reperfusion injury in the rat heart in vivo. Br J Anaesth 2001; 87:905-11
23. Krolikowski JG, Weihrauch D, Bienengraeber M, Kersten JR, Warltier DC, Pagel PS: Role of Erk1/2, p70s6K, and eNOS in isoflurane-induced cardioprotection during early reperfusion in vivo. Can J Anaesth 2006; 53:174-82
24. Weber NC, Stursberg J, Wirthle NM, Toma O, Schlack W, Preckel B: Xenon preconditioning differently regulates p44/42 MAPK (ERK 1/2) and p46/54 MAPK (JNK 1/2 and 3) in vivo. Br J Anaesth 2006; 97:298-306
25. Jenkins DP, Baxter GF, Yellon DM: The pathophysiology of ischaemic preconditioning. Pharmacol Res 1995; 31:219-24
26. Li GC, Vasquez JA, Gallagher KP, Lucchesi BR: Myocardial protection with preconditioning. Circulation 1990; 82: 609-19
27. Bein B, Renner J, Caliebe D, Hanss R, Bauer M, Fraund S, Scholz J: The effects of interrupted or continuous administration of sevoflurane on preconditioning before cardiopulmonary bypass in coronary artery surgery: Comparison with continuous propofol. Anaesthesia 2008; 63:1046-55
28. Sanada S, Asanuma H, Tsukamoto O, Minamino T, Node K, Takashima S, Fukushima T, Ogai A, Shinozaki Y, Fujita M, Hirata A, Okuda H, Shimokawa H, Tomoike H, Hori M, Kitakaze M: Protein kinase A as another mediator of isch-emic preconditioning independent of protein kinase C. Circulation 2004; 110:51-7
29. Smul TM, Lange M, Redel A, Burkhard N, Roewer N, Kehl F: Desflurane-induced preconditioning against myocardial infarction is mediated by nitric oxide. ANESTHESIOLOGY 2006; 105:719-25
30. Venturini G, Colasanti M, Ascenzi P: Aprotinin, the first competitive protein inhibitor of NOS activity. Biochem Biophys Res Commun 1998; 249:263-5
31. Ge ZD, Pravdic D, Bienengraeber M, Pratt PF Jr, Aucham-pach JA, Gross GJ, Kersten JR, Warltier DC: Isoflurane postconditioning protects against reperfusion injury by preventing mitochondrial permeability transition by an endothelial nitric oxide synthase-dependent mechanism. ANESTHESIOLOGY 2010; 112:73-85
32. Dedkova EN, Blatter LA: Characteristics and function of cardiac mitochondrial nitric oxide synthase. J Physiol 2009; 587:851-72
33. Moore PK, Handy RL: Selective inhibitors of neuronal nitric oxide synthase-is no NOS really good NOS for the nervous system? Trends Pharmacol Sci 1997; 18:204-11
34. Misko TP, Moore WM, Kasten TP, Nickols GA, Corbett JA, Tilton RG, McDaniel ML, Williamson JR, Currie MG: Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 1993; 233:119-25
35. Barrett-Connor E: Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. Circulation 1997; 95:252-64
36. Booth EA, Lucchesi BR: Estrogen-mediated protection in myocardial ischemia-reperfusion injury. Cardiovasc Toxi-col 2008; 8:101-13
37. Nuedling S, Kahlert S, Loebbert K, Doevendans PA, Meyer R, Vetter H, Grohé C: 17 Beta-estradiol stimulates expression of endothelial and inducible NO synthase in rat myocardium in-vitro and in-vivo. Cardiovasc Res 1999; 43: 666-74
38. Bae S, Zhang L: Gender differences in cardioprotection against ischemia/reperfusion injury in adult rat hearts: Focus on Akt and protein kinase C signaling. J Pharmacol Exp Ther 2005; 315:1125-35
39. Wang M, Crisostomo P, Wairiuko GM, Meldrum DR: Estrogen receptor-alpha mediates acute myocardial protection in females. Am J Physiol Heart Circ Physiol 2006; 290: H2204-9
40. Wang C, Chiari PC, Weihrauch D, Krolikowski JG, Warltier DC, Kersten JR, Pratt PF Jr, Pagel PS: Gender-specificity of delayed preconditioning by isoflurane in rabbits: Potential role of endothelial nitric oxide synthase. Anesth Analg 2006; 103:274-80
41. Song X, Li G, Vaage J, Valen G: Effects of sex, gonadec-tomy, and oestrogen substitution on ischaemic preconditioning and ischaemia-reperfusion injury in mice. Acta Physiol Scand 2003; 177:459-66
42. Pabla R, Curtis MJ: Endogenous protection against reper-fusion-induced ventricular fibrillation: Role of neuronal versus non-neuronal sources of nitric oxide and species dependence in the rat versus rabbit isolated heart. J Mol Cell Cardiol 1996; 28:2097-110
43. Pabla R, Curtis MJ: Nitric oxide fails to confer endogenous antiarrhythmic cardioprotection in the primate heart in vitro. Br J Pharmacol 2007; 150:893-8
44. Valen G, Hansson GK, Dumitrescu A, Vaage J: Unstable angina activates myocardial heat shock protein 72, endo-thelial nitric oxide synthase, and transcription factors NFkappaB and AP-1. Cardiovasc Res 2000; 47:49-56